

Affibody to Participate in Upcoming Healthcare Investor Conferences

Stockholm, Sweden, August 27, 2026. Affibody AB ("Affibody"), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced participation in two upcoming investor conferences, delivering an update on clinical data from the ongoing Phase 1 study evaluating the RLT candidate, ABY-271, in patients with HER2-positive metastatic breast cancer.

Morgan Stanley 24th Annual Global Healthcare Conference (New York City)

- Presentation and 1x1 Investor Meetings
- Tuesday, September 15

4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit (New York City)

- 1x1 Investor Meetings
- Thursday, September 17

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder, Patricia Industries, is a part of Investor AB.

Further information can be found at: www.affibody.com.

Investor Relations

Leigh Salvo, New Street Investor Relations, +1 510 693 5238, leigh@newstreetir.com

Media Contact

Richard Hayhurst, 59° North Communications, +44 (0) 7711 8215727, richard.hayhurst@59north.bio

Affibody Contact

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Attachments

[Affibody to Participate in Upcoming Healthcare Investor Conferences](#)